Pangea Laboratory

We are excited to announce the publication of the latest PrecisionBIOME® research paper in the International Journal of Molecular Sciences MDPI.

"Surface Topography, Microbial Adhesion, and Immune Responses in Silicone Mammary Implant-Associated Capsular Fibrosis" examines the relationship between silicone mammary implant surface roughness and its effects on antimicrobial inflammatory responses and proteome adhesion in wound environments.

NGS microbial analysis using PrecisionBIOME® revealed the microbiome associated with different silicone mammary implants (SMIs), exploring SMI topography-dependent microbial colonization.

We are very proud of our PrecisionBIOME® team for their contribution to this investigation over the past few years, and would also like to thank Ines S. and everyone else for their work on the paper.

Find it here: https://www.mdpi.com/1422-0067/25/6/3163

We are thrilled to announce a significant milestone in our journey towards transforming cancer diagnostics: Pangea Laboratory has been granted Breakthrough Device Designation by the FDA's Center for Devices and Radiological Health (CDRH) for our Bladder CARE™ Assay.

This non-invasive epigenetic assay has been approved for the quantitative detection of bladder cancer and Upper Tract Urothelial Carcinoma (UTUC) DNA from urine specimens, utilizing the unique Pangea collection device. Our assay is poised to complement the current standard diagnostic procedures for the initial diagnosis of bladder cancer and UTUC in patients presenting with hematuria and suspected of having either cancer.

This recognition from the FDA is a testament to our team's unwavering commitment to advancing cancer diagnostics and underscores the potential impact of the Bladder CARE™ Assay in improving the accuracy and speed of urothelial cancer detection, ultimately enhancing patient outcomes.

Our sincere thanks to our research collaborators at USC Urology - Dr. Siamak Daneshmand, Dr. Hooman Djaladat, Dr. Gangning Liang, Dr. Alireza Ghoreifi, Dr. Sanam Seyedian, Dr. Saum Ghodoussipour, and everyone whose work has helped us achieve this breakthrough.

Our latest PrecisionBIOME® paper, "A Single-Center Pilot Study Investigating the Effects of a Native Cross-Linked Extracellular Matrix with Polyhexamethylene Biguanide to Manage Chronic Lower Extremity Wounds Exhibiting Bacterial Contamination," has been published in Wound Management & Prevention!

When it comes to dealing with difficult chronic wounds, a quantitative test like PrecisionBIOME® can be a game changer for effective care by accurately identifying pathogens in a biofilm. Plus, the crucial antimicrobial resistance data it provides support the proper management of bacterial contamination. 🦠🔬🩹

Discover more about PrecisionBIOME® and its many applications on our website [LINK IN BIO]

Bladder CARE™ has been designed with an easy-to-use, non-invasive urine collection kit that can be used in a clinical setting or for at-home sample collection for bladder cancer diagnostic testing.

Get in touch to learn more about how we're making it more convenient and cost-effective to monitor at-risk patients: https://pangealab.com/bladdercare/

This Bladder Cancer Awareness Month, we're thrilled to share that the results of our joint work with the USC Institute of Urology was acknowledged and cited under "Future Directions" in the inaugural AUA/SUO guidelines for the Diagnosis and Management of Non-Metastatic Upper Tract Urothelial Carcinoma (UTUC).

Considering that approximately 30% of UTUC patients have a history of bladder cancer and 8-13% have concurrent bladder cancer at diagnosis, this recognition underscores the importance of research and innovation in improving the detection and treatment for urothelial cancers.

Read the full publication here: https://www.auajournals.org/doi/abs/10.1097/JU.0000000000003188

Explore the latest guidelines here: https://www.auanet.org/guidelines-and-quality/guidelines/non-metastatic-upper-tract-urothelial-carcinoma

Bladder Cancer is more common than you think - every year, there are over 80,000 new cases diagnosed within the USA. As with all cancers, early detection matters.

Bladder CARE™ is a non-invasive test that can significantly detect the presence of cancer cells at a minimum concentration of 0.046% cancer cells in urine samples, which is the equivalent of 1 cancer cell for every 2,200 normal cells. Preliminary data has shown that this novel biomarker-based test can detect bladder cancer cells 7 months ahead of cystoscopy.

Learn more about Bladder CARE™ today and support innovative research that could revolutionize the diagnosis and monitoring of bladder cancer: https://pangealab.com/bladdercare/

Any of these symptoms could be early warning signs of Bladder Cancer:

- Hematuria (blood or blood clots in the urine).
- Dysuria (pain or a burning sensation while urinating).
- Urinating frequently.
- Nocturia (feeling the need to urinate multiple times during the night).
- Urgency to urinate, but inability to pass urine.
- Unilateral lower back pain (pain on one side of the body).

May is Bladder Cancer Awareness Month! Share this post to raise awareness and support ongoing research in this field, like our novel early-detection test: https://pangealab.com/bladdercare

We're celebrating in style here at Pangea Laboratory!

Thank you to every single one of our team members for your dedication, expertise, and commitment to making a difference in our patients' lives.

Congratulations to the PrecisionBIOME® team on the publication of their latest paper in BMC Oral Health!

By decoding the highly diverse microbiome around dental implants, they were able to show that argon plasma pre-treatment of implant healing abutments can significantly reduce soft tissue inflammation and plaque accumulation while preventing advanced biofilm formation.

Read the paper here: https://bmcoralhealth.biomedcentral.com/articles/10.1186/s12903-023-02729-1

Learn how our research is revolutionizing urological cancer detection at the American Association for Cancer Research (AACR) Annual Meeting!

Drop by booth #2273 to learn more about how we're using DNA methylation biomarkers for the non-invasive and highly sensitive early detection of Bladder Cancer and UTUC.

Just published in The Journal of Urology: A Urine-based DNA Methylation Marker Test to Detect Upper Tract Urothelial Carcinoma: A Prospective Cohort Study.

Congratulations to our team members Paolo Piatti, Yap Ching Chew, Benjamin Jara, Lucy Sanossian, and Taikun Yamada on the publication of another paper.

We would like to thank the USC Institute Of Urology team at the USC Norris Cancer Center, especially Drs. Alireza Ghoreifi, Sanam Ladi Seyedian, Hooman Djaladat, and Siamak Daneshmand for their outstanding work exploring new clinical applications for Bladder CARE™ and showing how it significantly outperforms existing non-invasive modalities to detect UTUC.

Read it here: https://www.auajournals.org/doi/abs/10.1097/JU.0000000000003188

Congratulations to our team members Paolo Piatti, Taikun Yamada, Benjamin Jara, and Lucy Sanossian, plus their collaborators from the USC Institute Of Urology, a part of USC Norris Comprehensive Cancer Center.

Their abstract on "The Diagnostic Value of Urinary Cytology versus DNA Methylation Urine Biomarker Test for Surveillance of Non-muscle Invasive Bladder Cancer" was just accepted for poster presentation at the American Urological Association's meeting this April.

The team is thrilled to be able to share their findings: Preliminary results showed that Bladder CARE™ has high sensitivity and can predict the recurrence of NMIBC within a median of 7 months prior.

Visit our website today to learn more about Bladder CARE™: https://pangealab.com/bladdercare/

Wishing one and all a very Merry Christmas from the Pangea Laboratory team!

Pangea Laboratory is honored to announce that we have been named to the 2022 list of ! We are proud of the inclusive company culture we have created and thankful for our amazing team.

The Pangea team had an amazing time sharing all about Bladder CARE at the Society of Urologic Oncology show in San Diego. It was exciting to catch up with our partners from University of Southern California and other institutions and to meet so many new faces.

Catch the Bladder CARE™ team at the Society of Urologic Oncology conference later this week in San Diego! We will be there to educate clinicians on the uses of Bladder CARE™ and to offer sign-ups for our six-month free trial program.

To get in touch with us ahead of the show, email us at [email protected]

Clinical studies performed in collaboration with Zymo Research Corp. and the Institute of Urology at USC Norris Comprehensive Cancer Center using Bladder CARE™ demonstrated that this test has a sensitivity of 93.5%, a specificity of 92.6%, and a PPV and NPV of 87.8%, and 96.2%, respectively.

Pangea Laboratory is currently offering a free 6-month trial of Bladder CARE™ to urologists and oncologists. To learn more or to get literature to pass to your healthcare provider, get in touch with our team today: [email protected]

Today marks the Day of Thanks! We're honoring our researchers, laboratory team, and doctors working to advance better bladder health for everyone.

The Bladder CARE™ Test is a non-invasive quantitative test for the detection and surveillance of bladder cancer from urine samples.

Bladder CARE™ measures the methylation level of three bladder cancer-specific DNA biomarkers. Changes in DNA methylation are early events in cancer formation and allow Bladder CARE™ to detect the presence of the tumor earlier than other tests.

Clinical studies for Bladder CARE™ have been performed in collaboration with the Institute of Urology at USC Norris Comprehensive Cancer Center. To learn more about this test and our free trial, get in touch with us today: [email protected]

Bladder CARE™ is simple, fast, and non-invasive by design.

The whole process consists of three steps, after which a report is generated:
1) Urine samples are collected comfortably at home (or at the physician’s office, if preferred) using the provided Urine Collection Kit.
2) After the sample is received by Pangea Laboratory, DNA is isolated from the urine.
3) Bladder cancer biomarkers are analyzed with a qPCR reaction that delivers results in just a few hours.

To learn most about Bladder CARE™, visit our website today: pangealab.com

Why Offer Bladder CARE™:
• Non-Invasive: Simple urine sample collection which minimizes patient discomfort and saves time.
• Superior Sensitivity: With a sensitivity of 93.5% Bladder CARE outperforms other commercially available bladder cancer tests.
• Early Detection: Bladder CARE™ detects cancer recurrence 7 months before cystoscopy, allowing physicians and patients to take important decisions earlier.
• Compatible with Remote Testing: Urine samples can be collected conveniently at home, increasing patient access to screening and monitoring processes.

To learn more about this LDT, contact us today: [email protected]

The five-year recurrence rates of bladder cancer range from 63 to 75%, depending on the stage of the original tumor. Because of this, proper surveillance matters.

For most patients, testing is recommended at 3, 6, and 12 months in year 1, every 6 months in year 2, annually in years 3-5, and afterward as clinically indicated.

We have developed Bladder CARE to make monitoring more convenient and comfortable for patients. Samples for this non-invasive test can be self-collected by patients at home and sent back to our lab for processing. To learn more about this test and order a free kit for your practice, visit pangealab.com today.

November is Bladder Health Month, and we encourage you to take control of your bladder health with these key steps:

1. Speak up! The earlier you speak to your healthcare provider about any issues you may be experiencing, the sooner you can manage or treat any symptoms effectively and get tested for related bladder conditions. To find a provider offering the Bladder CARE test, get in touch with us today.
2. Stop smoking. To***co use greatly increases your chances of developing bladder cancer.
3. Drink plenty of water. The U.S. National Academies of Sciences, Engineering, and Medicine determined that an adequate daily fluid intake is 15.5 cups a day for men and 11.5 cups for women.

PrecisionBIOME® can detect pathogens that are difficult to grow and unculturable organisms for a thorough, unbiased, agnostic detection of infectious agents found in the specimen. PrecisionBIOME® testing can be highly useful when applied in cases of acute infections, before the onset of antimicrobial therapy, to determine the causative agents of an infection more quickly and accurately.

Medical practitioners in otolaryngology, podiatry, wound care and gynecology who would like to try this test for themselves can email [email protected] to request a test kit for their practice.

Our fully equipped CLIA-certified, CAP-accredited laboratory is able to flexibly accommodate different workflows depending on our partner's testing needs.

Whether simple or complex, we pride ourselves on delivering accurate and precise results. Depending on your needs, we are able to add additional technology and design customized workflows to analyze your samples. Our research and development team are constantly innovating new tools and techniques to meet the challenge of evolving testing requirements.

We specialize in high-throughput sequencing, delivering precise and accurate insights in a rapid and cost-effective manner. Whatever your testing targets, we can design a solution that’s right for you.

All our services include sample collection, extraction, library prep, sequencing, and comprehensive bioinformatics analysis. Our control over our testing supply chain also ensures the availability of testing kits that allow for the safe collection of samples, including the inactivation and stabilization of pathogens.

When detected at an early stage, the chances of surviving Bladder Cancer is high. However, low-grade bladder cancers also recur frequently, and require consistent surveillance.

Scientists at Pangea Laboratory are developing a completely non-invasive urine test that can help with the early detection of Bladder Cancer, so patients can get more timely care.

Licensed healthcare providers who are interested in joining the Bladder CARE™ trial can learn more on our website.

If you are a patient and interested in the Bladder CARE™ test, please ask your doctor to contact us.

Pangea Laboratory has performed almost 20,000 free COVID-19 PCR tests for the uninsured in Los Angeles and Orange County since March, 2022, turning around results within 24 hours.

As COVID cases rise again this summer, it's important to continue testing, no matter your insurance status.

To get your free COVID-19 test in Los Angeles, visit the following locations:
Echo Park: 1800 Park Avenue Los Angeles, CA 90026
Union Station: 811 N. Vignes Street, Los Angeles, CA 90012

For free COVID-19 testing in Orange County, call at (714) 805-7838

Not all at-home tests are the same.

🧪Self-tests: Samples are collected and processed at home, and the test kit will include instructions on how to interpret the results on-site, usually within an hour

🧪Self-collection tests: Samples are collected at home, and sent to a laboratory for analysis. The laboratory will then provide the results

We offer self-collection COVID-19 tests, with results delivered within 24 hours of receiving the samples at our Tustin-based laboratory. To order a test kit, visit sick.org